The hereditary angioedema therapeutics market size is expected to grow by USD 1647.38 million from 2022 to 2027, accelerating at a CAGR of 8.95%, according to Technavio Research. The Hereditary Angioedema (HAE) Therapeutics Market is growing due to the increased awareness among healthcare professionals leading to improved identification and reporting of cases. Advances in genetic testing also contribute by enabling accurate diagnoses, expanding the demand for specialized treatments. These factors collectively drive market expansion as more individuals receive proper diagnosis and require targeted therapeutic solutions. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read PDF Sample Report
Hereditary Angioedema Therapeutics Market: Company Analysis
- Adverum Biotechnologies Inc.
- Arrowhead Pharmaceuticals Inc.
- Attune Pharmaceuticals Inc.
- BioCryst Pharmaceuticals Inc.
- BioMarin Pharmaceutical Inc.
- CENTOGENE NV
- Cipla Ltd.
- CSL Ltd.
- Diapharma Group Inc.
- Intellia Therapeutics Inc.
- Ionis Pharmaceuticals Inc.
- KalVista Pharmaceuticals Inc.
- Pharming Group NV
- Pharvaris NV
- Takeda Pharmaceutical Co. Ltd.
To gain access to more companies landscape available with Technavio, buy the report
Hereditary Angioedema Therapeutics Market: Segmentation Analysis
The market has segmented by end-user (Hospital pharmacies, Retail pharmacies, and E-commerce), product (C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, and Others), and geography (North America, Europe, Asia, and Rest of World (ROW)).
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. Get the sample report here
Hereditary Angioedema Therapeutics Market: Driver
One of the key market drivers for the Hereditary Angioedema (HAE) Therapeutics Market is the improved awareness, diagnosis, and understanding of hereditary angioedema. The increasing prevalence of hereditary angioedema is being driven by enhanced awareness among healthcare professionals, improved diagnostic tools, and greater knowledge about the genetic basis and primary mechanisms of the condition. This has led to better recognition and reporting of cases, as well as a higher number of individuals seeking medical attention and accurate diagnosis for their symptoms. As a result, the market is expected to experience growth due to the increased demand for therapeutic solutions and treatments for hereditary angioedema.
Strategic alliances among market vendors are a key trend in the hereditary angioedema (HAE) therapeutics market. Identify key trends, drivers, and challenges in the market. Download sample report to gain access to this information
Pulmonary Edema Therapeutics: The predicted value for the pulmonary edema therapeutics market from 2021 to 2026 is USD 339.45 million at a progressing CAGR of 3.06%. This pulmonary edema therapeutics market forecast report extensively covers market segmentation by type (cardiogenic pulmonary edema and non-cardiogenic pulmonary edema) and geography (North America, Europe, Asia, and Rest of World (ROW))
Duchenne Muscular Dystrophy (DMD) Therapeutics Market: The global Duchenne muscular dystrophy (DMD) therapeutics market size is estimated to grow by USD 2,397.67 million at a CAGR of 21.2% between 2022 and 2027. Technavio has segmented the market into type is classified into biologics and small molecules, distribution Channel is classified into offline and online and the geography segment includes key regions such as North America, Europe, Asia, and the Rest of World (ROW)
Table of Contents:
- Executive Summary
- Market Landscape
- Market Sizing
- Historic Market Sizes
- Five Forces Analysis
- Market Segmentation by end-user
- Market Segmentation by product
- Customer Landscape
- Geographic Landscape
- Drivers, Challenges, & Trends
- Company Landscape
- Company Analysis
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.